Companies › Remedy
1 active drug program in 1 registered trial: 1 Phase 2; Psychiatry; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Midomafetamine Sodium-dependent dopamine transporter releasing agent; Sodium-dependent serotonin transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent | SLC6A3, SLC6A4, SLC6A2 | Phase 2 | Post Traumatic Stress Disorder | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06044675 | Midomafetamine | Phase 2 | Post Traumatic Stress Disorder | Psychiatry | Mar 2027 |
Definium Therapeutics US Draig Therapeutics Kadence Bio HB BioTech Beckley Psytech
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.